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Abstract: Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are
neurodegenerative disorders that exist on a disease spectrum due to pathological, clinical and genetic
overlap. In up to 97% of ALS cases and ~50% of FTLD cases, the primary pathological protein
observed in affected tissues is TDP-43, which is hyperphosphorylated, ubiquitinated and cleaved.
The TDP-43 is observed in aggregates that are abnormally located in the cytoplasm. The pathogenicity
of TDP-43 cytoplasmic aggregates may be linked with both a loss of nuclear function and a gain
of toxic functions. The cellular processes involved in ALS and FTLD disease pathogenesis include
changes to RNA splicing, abnormal stress granules, mitochondrial dysfunction, impairments to
axonal transport and autophagy, abnormal neuromuscular junctions, endoplasmic reticulum stress
and the subsequent induction of the unfolded protein response. Here, we review and discuss the
evidence for alterations to these processes that have been reported in cellular and animal models of
TDP-43 proteinopathy.
Keywords: amyotrophic lateral sclerosis; frontotemporal lobar degeneration; TARDBP/TDP-43;
RNA metabolism; mitochondrial dysfunction; proteostasis; proteinopathy
1. Introduction
Amyotrophic lateral sclerosis, the most common form of motor neuron disease, is
characterized by the progressive loss of upper and lower motor neurons, leading to death
2–4 years post-diagnosis, usually due to respiratory failure [1]. Frontotemporal lobar de-
generation is caused by the progressive loss of neurons in the frontal and temporal lobes of
the brain and is the second leading cause of early-onset dementia worldwide [2]. ALS and
FTLD exist on a disease continuum as they share clinical, neuropathological, and genetic
similarities [2]. Of note, 12.5% of FTLD cases have concomitant motor neuron disease, with
a further 30% showing signs of motor neuron dysfunction [3]. Similarly, 50% of ALS cases
have signs of cognitive decline, with 20% fitting the diagnostic criteria for FTLD [4]. The
pathobiology of ALS can include neuroinflammation, gliosis, glutamate-mediated excito-
toxicity and subsequent increased intracellular calcium, endoplasmic reticulum (ER) stress,
impairments to protein homeostasis (proteostasis) and axonal transport, mitochondrial
dysfunction, free radical accumulation due to increased oxidative stress and increased
apoptosis [5,6]. The underlying causes of these disease processes are largely unknown but
may, at least in part, be linked with the buildup of aggregated proteins, such as TDP-43,
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superoxide dismutase 1 or C9orf72 dipeptide repeats caused by hexanucleotide G4C2
repeat expansion [7].
A key characteristic of neurodegenerative diseases is the identification of abnormal
protein aggregates in neurons [8]. In up to 97% of ALS cases and the majority of non-
tau-related FTLD cases, these aggregates contain the human nuclear ribonuclear protein
TAR DNA-binding protein 43 (TDP-43), suggesting similar molecular mechanisms for the
two diseases [9–11]. Thus, ALS- and TDP-43-associated FTLD (FTD-TDP) are considered
TDP-43 proteinopathies. Mutations in TARDBP, coding for mutant TDP-43 proteins, are
a rare cause of ALS and FTLD [12]. Four percent of fALS and 1.5% of sALS are caused
by mutations in TARDBP, with most being missense mutations that affect the C-terminal
domain [13]. Mutations have very rarely been identified in FTLD cases, with and without
co-morbid ALS [14,15]. Of note, the TDP-43 observed in degenerating neurons in ALS
and FTLD tissues in both mutation and non-mutation cases is abnormally cytoplasmic,
hyperphosphorylated, ubiquitinated and often cleaved, giving rise to C-terminal fragments
(CTFs) [16–18]. TDP-43 is primarily a nuclear protein, thus the cytoplasmic mislocalization
and aggregation of TDP-43 are considered important pathogenic mechanisms in ALS and
FTLD. However, neuronal TDP-43-positive intranuclear inclusions are also observed [19].
The aggregation of TDP-43 may be a primary disease process, or a byproduct of a distinct
initiating pathological process. However, the removal of TDP-43 from its functional site in
the nucleus is likely to impact diverse biological processes that could include disruptions
to mRNA splicing, cryptic exon retention, polyadenylation, nuclear export, localization,
and translation [11]. TDP-43 has also been implicated in axon outgrowth [20], axonal
transport [21], mitochondrial function [22], and autophagy [23]. Thus, while the exact
contribution of TDP-43 cytoplasmic mislocalization and aggregation to disease progression
is unclear, both loss and gain of function are thought to be involved. In this review, we will
summarize and discuss the molecular mechanisms that have been identified in cellular and
animal models of TDP-43 proteinopathies.
2. Pathogenic Mechanisms of TDP-43 in Cell and Animal Models
While TDP-43 pathology is identified in almost all cases of ALS and non-tau-related
FTLD, the mechanisms underlying pathogenicity are varied and incompletely understood.
2.1. Neuron Morphology and Axonal Degeneration
Both conditional knockout [24] and TDP-43 overexpression [25–27] cause neuronal
degeneration and reduced cell viability. Overexpression of TDP-43 may contribute to ALS
pathogenesis via the formation of insoluble aggregates, leading to impaired axonal trans-
port of essential energy metabolizing organelles such as the mitochondria. This may result
in cytotoxicity and neuronal apoptosis. Knockout of TDP-43 may result in transcriptional
irregularities or aberrant mRNA splicing (Kitamura, A., 2018). The presence of various
mutations increases the stability of TDP-43, leading to higher expression levels, which
may contribute to pathogenesis [28]. It is possible that in non-mutation cases, there is a
trigger that leads to increased TDP-43 levels that impairs neuronal health. Alternatively,
there may be a trigger for TDP-43 translocation and aggregation in the cytoplasm. TDP-43
mutant proteins (p.M337V and p.Q331K) overexpressed in rat cortical neurons mislocalize
into cytoplasmic aggregates. These neurons, and also those overexpressing wild-type
TDP-43, displayed shorter axons and smaller growth cone sizes compared with control
cells, suggesting a role for TDP-43 in cytoskeletal regulation [25]. Similarly, overexpression
of mutant TDP-43 (p.A315T, p.Q331K or p.M337V), or TDP-43 lacking a nuclear localiza-
tion signal (∆NLS), led to abnormal neurite morphology and decreased cortical neuron
viability [26]. These studies suggest that the translocation of TDP-43 out of the nucleus is
critical to pathogenesis in TDP-43 proteinopathy involving dysfunctional axonal growth,
decreased axonal innervation and neuronal viability.
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Axon outgrowth is essential for neuronal communication and innervation of ac-
tion potentials in neuromuscular junctions (NMJs). TDP-43 has been implicated in axon
outgrowth and the denervation of NMJs, causing defective synaptic transmission, and
impacting cell survivability and conductivity. The overexpression of wild-type or mu-
tant TDP-43 (p.M337V or p.Q382T) in mouse primary neurons caused impaired axon
outgrowth. This was shown to be dependent on the C-terminal domain [29]. Further,
there was an increased number of degenerated axons in the ventral root of mice expressing
TDP-43A315T [30]. However, overexpression of TDP-43A315T in the primary cortical neurons
of a distinct transgenic mouse did not significantly affect dendrite or axon outgrowth [31].
Axonal destruction is a prominent feature of neurodegeneration and can also be caused
by injury via a process termed Wallerian degeneration, where an injury at a particular site
affects all axons simultaneously [32]. A critical gene in this pathway is sterile alpha and
TIR motif-containing 1. Deletion of this gene in a TDP-43Q331K mouse model of ALS-FTLD
reduced the degeneration of motor axons and the denervation of NMJs, thus implicating
Wallerian-like pathways in the axonal degeneration observed in ALS [33]. Denervation of
NMJs is a characteristic feature of ALS. In TDP-43Q331K transgenic mice, defective synaptic
transmission at the NMJ is observed at age 3 months, preceding the motor dysfunction
that was observed at age 10 months [34]. This fits with the theory that ALS is a ‘dying back’
disease, where denervation and degeneration occur before motor neuron loss [35]. Further
implicating TDP-43 in NMJ function, innervation of NMJs in the soleus muscle progres-
sively decreased with age in a knockin TDP-43N390D mouse [36]. Expression of TDP-43A315T
in mouse cortical neurons decreased the localization of the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropinionic acid (AMPA) glutamate receptor subunit GluR1 at dendritic spines,
which was associated with a reduction in the presynaptic marker synaptophysin [31].
Thus, denervation of NMJs and dysregulated synaptic function may be related to declining
neuronal function in ALS and FTLD. TDP-43 mislocalization may play a critical role in
causing ALS and FTLD axonal dysfunction.
2.2. Post-Translational Modifications
TDP-43 is primarily a nuclear protein [11]. Its translocation to the cytoplasm is
associated with various post-translational modifications (PTMs) including cleavage and
aggregation, acetylation, ubiquitination, SUMOylation and phosphorylation, which may
lead to toxic gain of function in the cytoplasm.
2.2.1. Cleavage
While TDP-43 is autoregulated at a transcriptional level, it is also degraded by both
the ubiquitin-proteasome system (UPS) and the autophagy-lysosome pathway, hereafter
autophagy [37]. It has been suggested that cleavage, or fragmentation, may be a prerequisite
to proteolytic degradation [38]. TDP-43 can be cleaved by caspase-3 and calpains [39].
There are multiple potential cleavage sites (Figure 1) that give rise to 15, 25 and 35 kDa
CTFs [40–43]. The consistent identification of phosphorylated and fragmented TDP-43 in
affected tissues suggests that cleavage and phosphorylation of accumulated TDP-43 may
be part of the pathological process in ALS and FTD-TDP [16,17,44,45]. Of note, while CTFs
are observed in the insoluble fractions of brain tissue from ALS and FTLD patients, they
are either not detected or are only faintly detected in spinal cord tissue [18,44].
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Figure 1. TDP-43 domain structure, potential caspase cleavage sites and CTFs. TDP-43 domain structure consists of an
N-terminal domain (NTD), a nuclear localizing sequence (NLS), two RNA recognition motifs (RRM1 and RRM2), a glycine-
rich domain and a nuclear export sequence (NES). Caspase-mediated cleavage sites are indicated with black triangles and
can occur between amino acid residues 8/9, 84/85, 89/90, 208/209, 214/215, 218/219 and 246/247. The major CTFs that
have been identified in patient tissues are indicated [41–43].
C-Terminal Fragments
When expressed in HEK293 cells, a 35 and a 25 kDa CTF formed cytoplasmic aggre-
gates in 25% and 75% of cells, respectively [45]. Expression of a CTF consisting of aa162-414
was phosphorylated and formed aggregates, and while cytotoxicity was observed after
7 days of expression, it was less cytotoxic than overexpression of full-length TDP-43, which
was not phosphorylated and did not aggregate [27]. Overexpression of TDP-43-∆NLS did
not aggregate or cause significant cell death. Thus, cleavage appears to precede aberrant
TDP-43 phosphorylation and cytoplasmic aggregation but may not be required for toxicity.
Expression of a 25 kDa CTF (aa208-414) in a transgenic mouse model induced hyperphos-
phorylation, insolubility and a punctate accumulation of TDP-43 in the cytoplasm, without
inducing the formation of large inclusion bodies. This was accompanied by neuron loss
in the hippocampus and astrogliosis [46]. However, earlier studies showed that while a
25 kDa CTF was more highly phosphorylated than full-length TDP-43, the formation of
inclusions and cytotoxicity was not dependent on CTF phosphorylation [45]. Furukawa
et al. (2011) showed that the formation and localization of inclusion bodies, or aggregates,
depends on the cleavage site (Table 1) [47]. Single nuclear inclusions were observed for
some CTFs (aa188-414, aa193-414, aa198-414 and aa203-414) whilst others (aa208-414, aa213-
414, aa220-414 and aa225-414) formed multiple cytoplasmic inclusions [47]. These CTFs
all had increased insolubility compared to full-length TDP-43 and were phosphorylated.
Proteins that corresponded to cleavage in more N-terminal regions (aa167-414, aa173-414,
aa178-414, aa183-414) had similar insolubility when compared to full-length TDP-43 and
rarely formed inclusion bodies. The authors showed that phosphorylation was not required
for insolubility, as TDP-43 aa208-414 with Serine to Alanine substitutions was insoluble.
Thus, phosphorylation may be a post-aggregation phenomenon [47]. Brady et al. (2011)
also showed that aggregation of TDP-43 with Serine409/410 to Alanine substitutions, while
reduced by ~15%, still occurred [48]. Taken together, it appears that it is cytoplasmic
aggregation, rather than the characteristic hyperphosphorylation of TDP-43, that is critical
to cytotoxicity. Wei et al. (2017) found that there may be two mechanisms responsible for
the increased propensity to aggregate and the toxicity of CTFs: abolishment of the RRM2
structure, or release of the C-terminal domain [49].
Translocation of TDP-43 out of the nucleus causes loss of function (see Section 2.2.1),
while the formation of cytoplasmic aggregates containing CTFs are thought to give rise to
toxic gain of function. When overexpressed, the TDP-43A315T mutant protein is fragmented
into persistent CTFs that resist proteolytic degradation [50]. The p.Q343R [51], p.G348C,
p.R361S and p.N390D [52], p.M337V, p.N345K and p.I383V [53], p.A382T and p.S393L [54]
mutant proteins also generate cleavage products of 25, ~28 or 35 kDa (Table 1). Overex-
pression of a 25 kDa CTF consisting of amino acids (aa) 208-414 is toxic to primary cortical
neurons, M17 neuroblastoma and HEK293 cells [45,55,56]. A further study showed that a
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25 kDa CTF was more susceptible to aggregation than a 35 kDa CTF when overexpressed.
The 25 kDa CTF was also significantly more cytotoxic than full-length TDP-43, whereas the
35 kDa CTF was not [56]. However, overexpression of CTFs did not decrease cell viability
compared to those expressing full-length TDP-43 in either NSC-34s or SH-SY5Ys, yet they
did impair neurite outgrowth [27,57]. The toxicity of CTFs generated by caspase cleavage is
dependent on the cytoplasmic translocation of TDP-43, as the fusion of an NLS to a 25 kDa
CTF attenuated Neura2A cell death [56]. The importance of the NLS to TDP-43 proteinopa-
thy and toxicity has been further demonstrated in ∆NLS mouse models [58–60]. A mouse
model with inducible hTDP-43∆NLS expression showed cytoplasmic accumulation of
insoluble, phosphorylated TDP-43. The mice exhibited significant neurodegeneration with
neuron loss, muscle denervation and progressive muscle impairment. Importantly the in-
duced return of nuclear TDP-43 expression rescued the neurodegeneration phenotype [60].
By contrast, a distinct hTDP-43∆NLS mouse model only rarely showed phosphorylated
cytoplasmic aggregates yet also gave rise to a phenotype resembling ALS. Pathogenesis
appeared to be due to reduced nuclear TDP-43 function, as profound gene expression
changes were observed [58]. Sasaguri et al. (2016) showed that mutation of a single residue
in the NLS, but not deletion of the extreme N-terminus (aa 1–9), caused cytoplasmic
accumulation of TDP-43 [59]. Using sequentially deleted N-terminal proteins, Nonaka
et al. (2009) found that aa 1–161 within the RNA recognition motif 1 (RRM1) domain are
required for the regulation of exon skipping in the cystic fibrosis transmembrane conductance
regulator gene [42]. Thus, CTFs generated due to mutations, that do not contain these
N-terminal amino acid residues may lose the ability to regulate RNA as well as gaining
toxic cytoplasmic functions.
2.2.2. Acetylation
Acetylation is an enzyme-mediated process whereby an acetyl group is moved from
one molecule to another to alter intracellular localization, protein–protein interactions or
tag proteins for degradation. Various TDP-43 RNA regulatory functions are impaired due
to acetylation. Specifically, RNA binding is inhibited by post-translational acetylation at
lysine residue 145 (Lys-145), which sits within the RNA-binding domain [61]. This led
to a reduction in splicing function. Acetylation of TDP-43 induced the aggregation of
insoluble, hyperphosphorylated TDP-43 within neuronal cells. TDP-43 became insoluble
and hyper-phosphorylated after cytoplasmic acetylation was induced through the use of
single and double acetylation mimics within TDP-43-∆NLS [61]. Insolubility and hyper-
phosphorylation are characteristic mechanisms of pathological TDP-43 inclusions displayed
in ALS and other TDP-43 proteinopathies. Cohen et al. (2015) analyzed spinal cord
tissue from ALS patients and found acetylated (Lys-145) and phosphorylated (p-Serine
409/410) TDP-43 lesions. Brain tissue from FTD-TDP patients failed to show the same result,
with only phosphorylated TDP-43 inclusions present. The absence of acetylation may be
explained by the fact that TDP-43 aggregates in FTD typically consist of CTFs beginning at
residue Arg-208, as such the residue that is acetylated (Lys-145) is not present [61]. A further
study using ALS brain tissue showed no acetylation at Lys-145 or Lys-192, instead reporting
acetylation at Lys-82 [62]. This indicates that there may be heterogeneity between patients.
Sanna et al. (2020) show that TDP-43, via its RRM1 and RRM2 domains, interacts
with histone deacetylase 6 (HDAC6). The RRM domains contain the two major acetylation
sites in TDP-43 Lys-142 and Lys-192 [63]. The authors used cell and drosophila models to
show that treatment with pan-HDAC inhibitors was protective against the toxicity induced
by overexpression of wild type or mutant TDP-43. Therefore, acetylation of TDP-43 may
be a potential therapeutic target in ALS and FTLD [63]. A new study highlighted the
mechanisms underlying TDP-43 acetylation related pathology. Yu et al. (2021) showed that
TDP-43 that was either unable to bind to RNA, or TDP-43 that was acetylated within the
RRMs underwent phase separation into anisosomes [64]. TDP-43 acetylation promoted the
formation of these liquid spherical shells with liquid cores. Of note, when ATP levels were
lowered, as can be seen in post-mortem tissues, these anisosomes transformed into protein
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aggregates, suggesting that anisosomes may be antecedents of the pathological aggregates
identified in patient tissues [64].
2.2.3. Ubiquitination
Attachment of ubiquitin to target proteins is a well-known signal for protein degrada-
tion. TDP-43 ubiquitination was one of the first signature modifications to be associated
with ALS and FTLD [18,42]. A mutagenesis study utilized mass spectrometry to show
that Lys-84, Lys-95, Lys-160, Lys-181 and Lys-263 are TDP-43 ubiquitination sites, with
Lys-84 implicated in the regulation of TDP-43 nuclear import. Lys-84 and Lys-95 were
investigated further and shown to have no effect on TDP-43 solubility [65]. The authors
also investigated 15 TDP-43 mutant proteins and showed that only one, p.K263E, was
heavily modified with ubiquitin. The remaining mutant proteins were ubiquitinated to a
similar extent as the wild-type protein. The pathological 35 kDa CTF (aa193-414) contains
4 Lysine residues. The authors showed that this fragment is heavily ubiquitinated and
that removal of at least 3 lysines was required to suppress ubiquitination [65]. However,
Lys-192 substitution with an Arginine decreased ubiquitination. Of note, in the context of
full-length TDP-43, ubiquitination of the C-terminal domain was not observed. This may
be explained if ubiquitination occurs following cleavage. Of note, p.Q331K and p.N345K
mutations did no display increased ubiquitination [65].
2.2.4. SUMOylation
The small ubiquitin-like modifier (SUMO) pathway involves enzymatic PTM, resulting
in the covalent attachment of SUMO proteins to a target protein’s lysine residues [66].
SUMOylation is a reversible and dynamic pathway that can compete with ubiquitin to
enact gene transcription modifications and alter subcellular localization or protein turnover.
Importantly SUMOylation plays a role in the cells response to oxidative stress, hypoxia
and glutamate excitotoxicity as well as proteasome impediment, all of which are aberrant
processes linked to motor neuron degeneration in ALS [66]. Various studies have shown
that SUMOylation of fused in liposarcoma, superoxide dismutase and TDP-43, al implicated
in ALS pathogenesis, occurs [67]. Overexpressed full-length TDP-43 or a splicing variant
resulted in an increase in the level of SUMO-2/3 and ubiquitin detected in cells, suggesting
that SUMOylation and ubiquitination may be interlinked. SUMO-2/3 was predominantly
colocalized with TDP-43 primarily in nuclear inclusions [68]. Maurel et al. (2020) identified
a unique consensus site for SUMOylation at lysine-136 of TDP-43 [69]. They further show
that replacement of this residue with an arginine altered the intracellular localization of
TDP-43 aggregates from the cytoplasm to the nucleus, indicating that SUMOylation of
this residue is critical to TDP-43 cytoplasmic localization [69]. However, it is not known
whether SUMOylation of TDP-43 creates a toxic species.
2.2.5. Phosphorylation and Aggregation
In addition to PTMs such as ubiquitination, oxidation and acetylation, phosphorylation,
the generation of CTFs, cytoplasmic accumulation and mutations are all factors that affect
TDP-43 aggregation [70]. Various CTFs (17 to 26 kDa) mislocalize to the cytoplasm [16,47]
and are associated with TDP-43 phosphorylation and sarkosyl insolubility [16].
Mutant TDP-43 Proteins
Expression of mutant TDP-43 (p.D169G, p.K181E, p.K263E [71] and p.Q331K [55])
leads to co-aggregation with endogenous wild-type TDP-43, whereas overexpression of
wild-type TDP-43 exacerbates p.Q331K aggregation [72]. In primary neurons, overex-
pressed TDP-43A315T was mainly present in the insoluble fraction, whilst overexpressed
wild-type TDP-43 was primarily soluble [50]. Some ALS-associated TDP-43 mutant pro-
teins, p.A315T and Y374X, but not others, p.M337V or p.A382T, were associated with
increased insolubility (Table 1). Yet, when introduced into a TDP-43 CTF (aa235-414),
p.M337V and p.Y374X increased the insolubility of the CTF, whereas p.A315T and p.A382T
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did not [47]. Another study investigated the effects of 14 ALS mutations on CTF (aa162-414)
inclusion formation. All increased the number of aggregates observed. However, only
half (p.D169G, p.G294A, p.Q331K, p.M337V, p.Q343R, p.N390D and p.N390S) reached
significance when compared with the wild-type CTF [42]. However, Fallini et al. (2012)
reported that while p.M337V and p.A382T TDP-43 mislocalize to the cytoplasm, they did
not exhibit increased aggregation [29]. Watanabe et al. (2013) tested the solubility and
localization of 18 ALS mutant TDP-43 proteins and found that while all had decreased
solubility, and 11 were less nuclear compared with wild-type (Table 1), neither measure
correlated with either disease onset or duration. However, increased stability (half-life) of
mutant proteins was associated with earlier disease onset [28].

















p.G290A N [28] Y [28] Y [28] Y [28]N [42]
p.S292N Y [28] Y [28] Y [28] Y [28]
p.G294A Y [42]
p.G294V N [28] Y [28] Y [28] Y [28]
p.G298S N [28] Y [28] Y [28] Y [28]N [42] Y [28]
p.A315T Y [28] Y [28,50,74] Y [28] Y [28,48,51,74,75]N [42,74] Y [28]
p.A315E N [28] Y [28] Y [28] Y [28]
p.M331V Y [28] Y [28] Y [28] Y [28]
p.S332N N [28] Y [28] Y [28] Y [28]
p.M337V Y [25]N [28] Y [28] Y [28]
Y [28,42,75]
N [29,47] Y [28]
p.Q331K Y [25,55] Y [55] Y [42]
p.Q343R Y [28] Y [28] Y [28] Y [28,75] Y [28]
p.N345K Y [28] Y [28] Y [28] Y [28]
p.G348C N [28] Y [28] Y [28] Y [28]N [42] Y [28]
p.G348V N [28] Y [28] Y [28] Y [28]
p.N352S Y [28] Y [28] Y [28] Y [28] Y [28]
p.R361S N [42]
p.Y374X Y [47]
p.N378D Y [28] Y [28] Y [28] Y [28]
p.S379P Y [28] Y [28] Y [28] Y [28]
p.A382T Y [28] Y [28] Y [28] Y [28]N [29,42,48] Y [28]














p.I383V Y [28] Y [28] Y [28] Y [28]
p.N390D Y [42]
p.N390S Y [42]






188-414 Y [47] single nuclearinclusion. Y [47]
193-414 Y [47] single nuclearinclusion. Y [47]
198-414 Y [47] single nuclearinclusion. Y [47]
203-414 Y [47] single nuclearinclusion. Y [47]


















The formation of TDP-43 into oligomers is an intermediary step that occurs before
aggregate formation [76]. Oligomerization of TDP-43 transpires via its N-terminus and
enables it to function as a modulator of RNA splicing [77]. Full-length TDP-43 forms
oligomers in FTD-TDP patients that are toxic [78]. However, dysfunctional oligomerization
of mutant TDP-43 can lead to the formation of insoluble aggregates and result in cytotoxicity.
Abnormal disulphide-crosslinked TDP-43A315T oligomers were isolated from the cortical
tissue of mice expressing this protein under the prion promoter, and high-molecular-weight
poly-ubiquitinated TDP-43 aggregates were isolated from the spinal cord [30]. When ex-
pressed in motor neuron-like cells, both wild-type and mutant (p.Q331K and p.M337V)
TDP-43 translocated into cytoplasmic aggregates in response to oxidative stress [79]. The
authors found that both cysteine-dependent insoluble oligomers and cysteine-independent
aggregates formed. This was not dependent on the presence of a mutation, but rather
was reliant on the presence of the N-terminal domain. The authors were able to distin-
guish between oligomer formation and aggregation. It was shown that 35 and 25 kDa
CTFs localize into oligomers when full-length TDP-43 is co-expressed but are observed in
Int. J. Mol. Sci. 2021, 22, 4705 9 of 34
large aggregates when an N-terminal deletion protein was co-expressed [79]. Conversely
the N-terminal domain is stabilized by disulphide bridges at cysteine residues 39 and
50, and dimerization prevents cytoplasmic aggregate formation [80]. A TDP-43C39S/C50S
double mutation almost completely abolished oligomer formation. Thus, oxidation of these
residues is important for the initiation of oligomerization. Of note, the substitution of any of
the other 4 cysteine residues in TDP-43 to serine or alanine caused hyper-aggregation [79].
Aggregation of mutant proteins, such as TDP-43, is viewed as toxic proteinopathy in neu-
rodegenerative diseases such as ALS. It is currently controversial as to whether aggregates
are inherently toxic or are byproducts that act as toxicity markers.
Aggregate Toxicity
There has been debate as to whether TDP-43 aggregation is by itself toxic. Phosphory-
lation of TDP-43 by casein kinase 1ε (CK1ε) appears to increase the propensity of TDP-43 to
aggregate in response to oxidative stress [81]. Indeed, expression of a hyperactive CK1ε in-
creased TDP-43 aggregation and this was linked with decreased cell viability [82]. However,
Barmada et al. (2010) showed that it is TDP-43 cytoplasmic mislocalization, rather than ag-
gregation, that is the predictor of neuronal death [83]. Consistent with this finding, Sasaguri
et al. (2016) observed that TDP-43-∆NLS rarely aggregated, however its overexpression
was toxic to primary neurons [59]. However, as discussed previously, expression of a ∆NLS
construct in SH-SY5Y cells did not aggregate and was not cytotoxic [27]. Of note, a mouse
model overexpressing TDP-43-∆NLS displayed a neurodegeneration phenotype, yet TDP-
43-∆NLS was only observed in cytoplasmic aggregates in a small percentage of cells [60].
Overexpression of TDP-43-∆NLS caused cytoplasmic co-aggregation/homodimerization
of the deletion protein with the endogenous full-length protein. This was associated with
impaired neurite outgrowth and was dependent on the presence of the extreme N-terminus
(amino acids 1–10) [84]. Mutation of the NLS in mice leads to gliosis and motor deficits,
whereas deletion of the first 9 amino acids of the N-terminus reduces aggregate formation
and toxicity [59]. Thus, the aggregation and toxicity of overexpressed TDP-43 appear to be
partially mediated by the extreme N-terminus. However, it may be translocation out of the
nucleus that causes toxicity.
Given that the majority of ALS and FTLD cases with TDP-43 proteinopathy are not
caused by TARDBP mutations, it is important to understand the role of aggregated and
mislocalized wild-type TDP-43 in disease pathogenesis. Transfection of SH-SY5Y cells
with purified bacterially expressed wild-type TDP-43 aggregates caused decreased cell
viability due to an increase in reactive oxygen species (ROS) and exacerbated caspase-3
activation [85]. Overexpression of full-length TDP-43, but not TDP-43-∆NLS or CTF aa162-
414, caused cleavage of poly-(ADP-ribose)polymerase-1 (PARP-1), a well-known substrate
of caspase-3 in apoptosis initiation [27]. Further arguing against a role for aggregation
of TDP-43 in neurotoxicity, some expression models of wild-type TDP-43 are cytotoxic
whilst rarely showing aggregation [25,27]. There have been inconsistent results in mice
overexpressing TDP-43. Some mouse models expressing human wild-type TDP-43 cause
neurodegenerative phenotypes [86,87], while others did not [72]. A mouse expressing
the human TDP-43A315T transgene developed progressive and fatal neurodegeneration,
with selective vulnerability of spinal cord neurons and neurons from the frontal cortex.
However, TDP-43 aggregates were not present, reinforcing that altered TDP-43 function is
required for neurodegeneration to occur, independent of aggregation [74].
2.3. Loss of Nuclear Function
TDP-43 is primarily located in the nucleus of cells. However, it can also be present
in the cytoplasm. This nucleocytoplasmic shuffling is mediated by nuclear localization
and nuclear export signals. The loss of nuclear TDP-43 due to abnormal cytoplasmic
mislocalization is thought to lead to loss-of-function effects and contribute to disease
pathogenicity in ALS [88].
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2.3.1. RNA Splicing and RNA Instability
Autoregulation
TDP-43 has key roles in the metabolism, processing, alternative splicing and transport
of RNA [89]. TDP-43 binds to long clusters of UG-rich sequences, which are found in
one-third of transcribed genes. Thus, TDP-43 regulates the processing of up to thousands of
transcripts, including that of its own transcript [90]. Autoregulation of TDP-43 establishes a
tightly regulated feedback loop. It has been demonstrated that a 2-fold increase or decrease
in TDP-43 concentration is sufficient to cause neurodegeneration [90]. TDP-43 recognizes
the 3′ untranslated region (UTR) that triggers alternative splicing of the transcript of introns
6 and 7 within the final exon of TDP-43 mRNA, thereby destabilizing the mRNA and
ultimately reducing protein expression [90,91]. The splicing event establishes exon–exon
junctions which induce the introduction of exon-junction complexes, comprised of eIF4α-III,
Magoh, Y14 and UPF3. These complexes stall translation and permit association between
the SURF complex (SMG1, UPF1 and eRF1 and 2) and the halted ribosome. The established
complex interacts with a stop codon >50 nucleotides downstream, phosphorylating UPF1
and activating nonsense-mediated decay of the transcript [90]. Induced TDP-43 expression
decreases the level of endogenous protein expressed. Thus, TDP-43 autoregulates via
a negative feedback loop. In mouse models that heterozygously express either human
TDP-43 p.A382T or p.G348C, silencing of the mutant allele led to a 1.5-fold increase in
expression of the endogenous wild-type protein. Thus, mutant TDP-43 participates in the
autoregulation feedback loop [92].
mRNP Granules
mRNAs are trafficked in dendrites and axons as ribonucleoprotein (mRNP) gran-
ules that consist of mRNAs, RNA-binding proteins (RBPs), ribosomes and translation
factors [93,94]. mRNP granules are transported by microtubules to deliver mRNA to distal
compartments in neurons. TDP-43 accumulates within these granules in the cytoplasm
and facilitates RNA trafficking [21]. Expression of TDP-43 mutant proteins (p.M337V and
p.A315T) impaired the transport of target mRNAs in mouse cortical neurons, as gran-
ules were more often immotile and had an increase in retrograde movement compared
with cells expressing wild-type TDP-43 [21]. These findings were confirmed in motor
neurons derived from ALS patient-induced pluripotent stem cells (iPSCs) harboring muta-
tions (p.M337V, p.A315T and p.G298S) [21]. In another study, mRNP granules containing
ALS-linked mutant TDP-43 (p.G298S and p.M337V) had decreased motility and increased
viscosity. The transport of mutant TDP-43 RNP granules was interrupted more than
wild-type granules, with stalling or halting observed when granules interacted [95]. The
transport and translation of mRNA in neurons are interlinked, with mRNAs remaining
inactive until they are unmasked by activation signals. TDP-43 was shown to co-operate
with the RNA-binding proteins fragile X mental retardation protein or Staufen1 to regulate
anterograde or retrograde transport of mRNP granules, respectively [96]. RNAi-mediated
depletion of TDP-43, FMRP or Staufen1 significantly altered the movement of endogenous
Rac1 [96]. Chu et al. (2019) show that TDP-43 regulates the dynamics and kinetics of
coupled mRNA transport (microtubule-dependent) and translation in the dendrites of
mouse hippocampal neurons [96]. When the RRM domains are unable to bind to RNA
toxicity is reduced, indicating that TDP-43 binding to RNA may be an important factor in
ALS and FTLD pathogenesis [97–100].
Splicing
TDP-43 has a critical role in repressing splicing to protect the transcriptome [101].
Using a global proteomic approach, TDP-43 was shown to have an extensive network
of interaction partners that are known to regulate RNA metabolism, including a nuclear
splicing cluster and a translation cluster [102]. TDP-43 associates with factors important
for the splicing and transport of RNA [102–104]. These interactions can be RNA-binding
dependent or independent [102]. Depletion of TDP-43 in mice led to alterations to the level
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of 601 mRNAs including fused in sarcoma/translocated in liposarcoma (FUS/TLS), progranulin
and other genes associated with neurodegeneration. Using splicing-sensitive microarrays,
TDP-43 was found to be important for the maintenance and splicing of more than 1000 mR-
NAs. The RNAs that were most reduced by TDP-43 knockdown encoded proteins that are
important for synaptic activity [105]. While it seems plausible that a loss of function due to
cytoplasmic mislocalization may contribute to ALS and FTLD pathogenesis via reduced
RNA regulation, the presence of the p.A315T or p.M337V mutations did not significantly
affect the interactome [102].
In mutant mice expressing high levels of TDP-43Q331K, which develop adult-onset
ALS symptoms, exon exclusion in some pre-mRNAs was enhanced compared to mice
expressing human wild-type TDP-43. Of note, TDP-43Q331K increased the normal splicing
of some TDP-43 targets, while other targets exhibited a loss of splicing function that
mimicked changes observed due to reduced TDP-43 activity [106]. Some exons were
misregulated by increased expression of wild-type or mutant TDP-43, but not by TDP-43
deficiency [106]. ALS-associated TARDBP mutations near the RRM domains (p.K181E,
p.D169G and p.K263E) disrupt RNA binding and also cause sequestration of wild-type
TDP-43 in cytoplasmic inclusions, suggesting that RNA binding may be linked to TDP-
43 solubility [71]. Of note, inhibition of TDP-43/RNA interactions, mediated by the
RRM domains of TDP-43, by a small molecule (rTRD01) partially rescued the locomotor
dysfunction observed in a TARDBP mutation (p.A315T) drosophila model of ALS [107].
Using two strains of mice generated through N-ethyl-N-nitrosourea (ENU) mutagenesis,
Fratta et al. (2018) were able to identify a mutation-associated (p.F201I) novel splicing
event that involves the skipping or inclusion of constitutive exons, referred to as “skiptic”
exons, to alter gene expression [108]. The mutations were present within the RRM2 domain
(p.F210I) and the C-terminal domain (p.M323K). The p.M323K mutation was shown to
affect TDP-43 phase separation, similarly to the ALS-associated p.Q331K mutation. The
ENU-induced mutations were shown to have loss (p.F210I) or gain-of-function (p.M323K)
splicing effects on exon inclusion in the CTFR and Sortilin-1 genes, while 47 skiptic exons
were differentially regulated in the p.F210I strain. The skiptic exons identified in the
p.M323K strain were absent in the p.F210I strain. Of note, the p.F210I mutation had
similar effects transcriptome wide as shRNA-mediated TDP-43 knockdown. The p.M323K
mutation had opposing effects and led to the skipping of constitutive exons in a distinct
set of 44 genes, including 7 genes from the UPS [108]. Importantly, in p.M323K mice, a
progressive neuromuscular phenotype involving loss of grip strength and muscle force
and a significant reduction in motor units was observed. The mice also showed p62
and ubiquitin-positive inclusions, reminiscent of neurodegenerative disease states, and
upregulated Tardbp mRNA levels. By contrast, the p.F210I loss-of-function mice did not
display a motor phenotype when aged up to 2 years [108].
The causes of TDP-43 translocation out of the nucleus are unknown but may include
genetic (mutation) or environmental factors. A p.M337V transgenic pig model of ALS that
exhibits a severe phenotype was used to investigate the role of cytoplasmic mislocalization
on RNA splicing events [109]. TDP-43 was observed to be cytoplasmic in neuronal cells
and caused mislocalization of splicing factor proline-glutamine rich (PSF), and NeuN
(neuronal nuclei), which regulates splicing of RNA. Expression of the mutant TDP-43 led
to the increased production of an exclusion isoform of NMHC II-B (myh 10), which is
important for the regulation of N-methyl-d-aspartate receptor trafficking and neuronal
function and is regulated by PSF and NeuN. Protein analysis confirmed that there was
decreased NMHC-II B. Importantly, mislocalization of PSF and NeuN to the cytoplasm
was also observed in ALS patient brain tissue [109]. In a homozygous knockin mouse of
TDP-43M337V, which did not show a motor phenotype, mRNA splicing was deregulated,
including that of Kcinp2, Sort1, Sema3f [110]. Thus, environmental or genetic factors that
induce TDP-43 cytoplasmic mislocalization may contribute to ALS and FTLD pathogenesis
via altered mRNA splicing.
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TDP-43 deficiency in mouse embryonic stem cells decreased the splicing of non-
conserved cryptic exons, leading to the incorporation of these exons into the mRNAs,
translation and subsequent nonsense-mediated decay. Reduced TDP-43 repression of
these exons was also observed in cases of ALS and FTLD [111]. The authors fused the
N-terminus of TDP-43 to a well-characterized splicing repressor domain to determine that
TDP-43 repression of these exons was important for cell viability [111]. In drosophila, null
mutants of TBPH (TDP-43 homologue) led to altered transcript splicing, including that of
a cacophony, a voltage-gated calcium channel. This affected neuromuscular junctions. Of
note, expression of cacophony rescued the locomotion phenotype indicating that changes
to splicing due to TDP-43 are functionally significant in ALS [112].
RNA Binding and Regulation of Gene Expression
TDP-43 promotes mRNA instability by interacting with Caf1, and thereby facilitates
RNA deadenylation, which is the rate-limiting step of mRNA decay [113]. Depletion of
TDP-43 by lentiviral shRNA in embryonic mouse motor neurons leads to defects in axon
outgrowth along with transcriptional changes (118 upregulated and 136 downregulated
transcripts), impaired protein synthesis and mitochondrial function in axonal subcellular
compartments [114]. The mRNAs that were downregulated were shown to have TDP-43-
binding sites in the 3′ UTRs, where those that were upregulated had fewer interaction
sites in their 3′ UTRs [114]. Expression of a chimeric repressor consisting of the TDP-43
RRM domain fused with an unrelated splicing repressor (Raver1) reduced the motor defect
of a conditional motor neuron TDP-43 knockout mouse, extending lifespan [101]. This
suggests that TDP-43-mediated repression of mRNA translation may be dysfunctional
in ALS and FTLD. Using patient-derived cells from sporadic ALS- and C9orf72 repeat-
positive ALS cases, Tank et al. (2018) observed a severe destabilization of RNA transcripts.
This destabilization was mirrored by overexpression of TDP-43. The authors show that
energy production may be impeded, while protein synthesis was increased, potentially
as compensatory mechanisms. Reduced transcripts for oxidative phosphorylation genes
and ribosome protein-coding RNAs were also observed in the spinal cord from ALS pa-
tients [104]. Recognition motifs for RBPs, including TDP-43, were enriched among the
RNAs that had altered stability, indicating that RBPs may be important for pathogene-
sis [104]. Using chromatin isolation by RNA purification and omics strategies, TDP-43
was found to bind to the neuron-specific long-non-coding RNA neuroLNC [115]. TDP-43
was further required for critical processes in neuronal development and promoted the
stabilization of selected mRNAs important for synaptic processes. Blocking the interaction
between neuroLNC and TDP-43 abolished the exocytotic release of neurotransmitters at
the synapse that is mediated by neuroLNC [115].
Expression of p.Q331K or p.M337V mutant TDP-43 in mice leads to a motor pheno-
type [106,116] and may be related to changes to the translatome of motor neurons [117].
Expression of TDP-43A315T in mice led to upregulation of SYNGR4 and downregulation of
PLEKHB1. These changes were also observed in an additional mouse model expressing
TDP-43Q331K [117]. The functions of these proteins in motor neurons are unknown but
may involve modulation of vesicular protein transport (via SYNGR4) or impact G protein-
coupled signaling and protein trafficking via interaction with myosin (Pleckstrin homology
domain-containing protein family B member 1) [117]. In NSC-34 cells and primary cortical
neurons, overexpression of either wild-type or p.A315T enhanced translation of Camta1,
Mig12 and Dennd4a mRNAs. Camta1 and Dennd4a are associated with neurodegener-
ation, thus TDP-43 regulation of these transcripts may be involved in ALS and FTLD
pathogenesis [118].
TDP-43 binds to the 3′ untranslated region to promote instability of mRNA transcripts
of tau, vascular endothelial growth factor A and progranulin, all implicated in ALS and/or
FTLD [91,119,120]. Another target mRNA of TDP-43 is the autophagy regulator Atg7. A
mutant TDP-43 lacking the RRM1 domain had impaired ability to bind to and stabilize
Atg7 mRNA, leading to impaired autophagy [121]. TDP-43 also represses cryptic isoforms
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of Atg4 [111]. A further autophagy-related target of TDP-43 is raptor [122]. Thus, TDP-
43 appears to be important for autophagy regulation (see Section 2.4.5.). However, the
mRNA with the greatest increase in binding in FTLD-TDP brain tissue compared with
controls was to the non-coding RNAs nuclear paraspeckle assembly transcript 1 (NEAT1)
and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1; also known as
NEAT2) [123]. Decreased binding was observed for the neurexin 3 and glial excitatory
amino acid transporter 2 (EEAT2) transcripts. EEAT2 is involved in the clearance of
glutamate at the synapse. The majority of altered cDNAs identified mapped to introns,
thus the authors speculated that TDP-43 might be regulating splicing of these mRNAs.
Indeed, following knockdown of TDP-43 they found alternative splicing including in those
mRNAs that are important for neuronal development and survival [123].
TDP-43 and has a regulatory role in gene expression and silencing and the stress
response via interaction with G-quadruplex (G4)-RNA. G4 is a structure found in DNA or
RNA that are rich in guanines. The structure of G4 is important for long-distance transport
and translation of mRNA in neurons. Ishiguro et al. (2020) investigated the effects of 10
randomly selected ALS mutants (p.D169G, p.N267S, p.G287S, p.G295S, p.A315T, p.G348C,
p.P363A, p.S379P, p.N390D and p.D247A) on interaction with G4-RNA in HEK293 cells.
All mutant proteins showed reduced G4-RNA binding and decreased trafficking of G4-
RNA [124]. As all mutations tested were located within the glycine-rich region, this may be
crucial for TDP-43 binding to G4-RNA and RNA transport. A small molecule that displaces
G4-RNA from TDP-43 complexes prevented toxicity in a drosophila TDP-43 ALS model,
suggesting that the G4 structure may be important for pathogenesis [107].
2.4. Gain of Toxic Cytoplasmic Function
2.4.1. Stress Granules
Stress granules are protective cytoplasmic granules that form in response to cellular
insults to protect and sequester non-essential mRNA transcripts (117Stress granules se-
quester stabilized mRNA transcripts that are not required for a cellular defense mechanism,
therefore establishing a cellular transcript bias promoting cellular survival factors [125].
Stress granules are observed following heat shock, osmotic stress, oxidative stress, nutri-
ent starvation, endoplasmic reticulum stress, UV radiation and viral infection [125–127].
In response to stress, signaling pathways are initiated to alter gene expression by either
transcriptional alterations or through post-translational modifications that alter RNA-
binding proteins [128]. Stress granule composition consists of RNA-binding proteins,
polyA-binding proteins, 40S ribosomal subunit, protected mRNAs and eukaryotic initia-
tion factors [129]. RNA-binding proteins, such as TDP-43, are integral to the formation and
regulation of stress granules [120]. TDP-43 has been identified in stress granules in vivo
and functions to regulate stress granule assembly and disassembly [68,108,120]. Stress
granules present a probable precursor to TDP-43 proteinopathies observed in cases of ALS
and FTLD [119]. The initiation of stress granule formation is coupled to the phosphoryla-
tion of eukaryotic initiation factor 2 alpha (eIF2α) [125]. Phosphorylation of eIF2α disrupts
the ribosomal formation around translating mRNA transcripts by blocking the formation
of the initiation complex eIF2α-GTP-tRNAmet. Disrupting the initiation complex from
binding to ribosomes permits the binding of T-cell intracellular antigen 1 (TIA-1) to the
48S ribosomal complex [125]. TIA-1 binding to the ribosomal subunit promotes its disas-
sembly and subsequent assembly of stress granules [128]. TIA-1 and RasGAP-association
endoribonuclease (G3BP) are integral stress granule proteins. G3BP is a nucleator of stress
granules involved in assembly [130]. TDP-43 regulates both TIA-1 and G3BP at the mRNA
level as silencing TDP-43 promotes the expression of TIA-1 by 130% while reducing G3BP
expression by 79% [128]. Additionally, siRNA knockdown of TDP-43 decreased the size of
stress granules and decreased the rate of stress granule assembly. As such, cells lacking
TDP-43 demonstrated a greater sensitivity to stress [128].
RNA-binding proteins are integral to the function and maintenance of stress granules.
TDP-43 is considered an important regulator of stress granule assembly, disassembly and
Int. J. Mol. Sci. 2021, 22, 4705 14 of 34
maintenance. Using a global proteomics approach in an over-expression model of FLAG-
tagged TDP-43 in HEK293 cells, an interactome of 126 proteins was identified that uniquely
bound to TDP-43. Of these, 15 proteins are associated with stress granules [102]. Studies
performed in HeLa cells demonstrate that TDP-43 co-localizes with stress granule markers
during oxidative stress [128]. Studies in patient lymphoblast cells expressing TDP-43WT,
TDP-43D169G or TDP-43R316S demonstrated that following sodium arsenate treatment, the
mutant TDP-43 were more resistant to stress granule disassembly [128]. Therefore, TDP-43
assists in both the assembly and disassembly of stress granules during times of stress.
Further mutational studies of TDP-43 reveal conflicting results regarding the role of TDP-43
in stress granule dynamics. Mutants p.A315T and p.Q343R are increased in the insoluble
fraction of cells, which also contained stress granule markers such as TIA-1 [131]. Mutant
p.M337V displays increased cytoplasmic mislocalization, but had a reduced association
with TIA-1 and reduced the number of cells containing stress granules. Thus, TDP-43
mislocalization into the cytoplasm and altered stress granule dynamics may be intrinsically
linked [116]. When expressed in patients’ primary fibroblasts the p.A315T mutant protein
did not translocate to stress granules. However, expression of TDP-43A315T resulted in
the downregulation of G3BP by 78% [130]. Thus, a loss of G3BP may be responsible for
stress granule assembly difficulties in cells expressing mutant TDP-43. The most prevalent
TDP-43 mutation, p.G348C, inhibits the formation of stress granules. Furthermore, TDP-43-
∆NLS proteins impaired stress granule formation revealing the possibility that reduced
nuclear TDP-43 in ALS and FTLD may impair stress granule formation [75]. A screen
of over 9000 compounds identified small molecules that impair TDP-43 binding to RNA
and recruitment to stress granules, while extending survival in a TDP-43 overexpression
mouse model of ALS [132]. Thus, impaired stress granule formation may be critical to
ALS pathogenesis.
2.4.2. Phase Separation
Liquid–liquid phase separation (LLPS) is the phenomenon that drives the formation
of membrane-less organelles and protein aggregation [129]. The low complexity C-terminal
domain of TDP-43 contributes to the LLPS of stress granules and cytoplasmic bodies
observed in ALS/FTLD patients [126]. Liquid–liquid phase separation of RBPs drives
the formation of liquid droplet-like RNP granules that lack a membrane. Stress induced
by arsenic treatment leads to the formation of liquid droplet-like nuclear bodies that
are dynamic and reversible and protected against cytotoxicity [73]. Granules formed
in SH-SY5Y cells demonstrated both cytoplasmic and nuclear TDP-43 bodies that were
0.2–1 µM in size. TDP-43 overexpression increased granule size to 1–3 µM [133]. The
axonal localization of TDP-43 granules in rat primary cortical neurons alters granule
dynamics [95]. TDP-43-positive granules located in the proximal axon are less dynamic
and more stable compared to mid axonal granules. The differences in granule dynamics
may arise through maturation of the oligomerized granule into a more fibrillated state. The
proximal localization of granules may confer the possibility of granule aging/persistence
as a component in the progression of ALS. Additionally, proximal localization of TDP-43
aggregates confers a greater resistance to chemical modulation by 1,6-hexanediol [95].
Of note, ALS-linked mutants p.M337V and p.G296S disrupt TDP-43 granule dynamics.
Mutant granules displayed less efficient transport and incomplete recovery. The C-terminal
mutant TDP-43 containing granules display a 20-fold increased viscosity and had greater
resistance to 1,6-hexanediol treatment, thereby demonstrating greater internal stability [95].
The liquid–liquid phase separation of TDP-43 is regulated through the low complexity
domains. The C-terminal domain of TDP-43 is a 160-residue domain that contains very
low sequence complexity that contains only a single alpha-helix between residues 321 and
330 [134]. The majority of disease-causing mutations are identified in this C-terminal
domain of TDP-43. Residues 331–340 regulate the helix structure with Trp334 initiating
the folding of the secondary structure [135]. Glycine residues at residue positions 335 and
338 are inhibitors of helix formation outlining potential regulatory elements. The ALS-
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linked mutant p.G335D contained enhanced alpha helical structures [134]. The helical
structure inside the C-terminal region of TDP-43 is critical for the formation of granules
mediated by LLPS. Fragmented TDP-43 (CTFs) is observed in ALS patients. An intact C-
terminal domain reduces solubility and affect phase separation into cytoplasmic granules
or their disassembly [134]. Several ALS-linked mutants including p.M337V, p.A321G,
p.A321V and p.Q331K disrupt the helix interaction inside the C-terminal domain. This
disruption results in the increased propensity of TDP-43 to phase separate and lead to
insoluble aggregates [134].
Phase separation and the formation of stress granules present a possible precursor
to cytoplasmic aggregates of TDP-43 [136]. TDP-43 granules co-localize to known stress
granule proteins such as fused in sarcoma/translocated in liposarcoma, human ribonuclear
protein A1 and TIA-1. In addition, arsenic-induced stress promotes the formation of TDP-
43 immobile bodies and demonstrates a connection between stress granules and TDP-43
aggregation [137]. However, there is evidence suggesting that TDP-43 granules co-localize
either dependently or independently of stress granule markers [138]. The recruitment
of TDP-43 into stress granules is correlated to the types of stress encountered by the cell.
Following acute stress, TDP-43 is not recruited to stress granules [138]. With chronic stress,
however, TDP-43 is recruited to stress granules regardless of the ALS-linked mutation,
suggesting that TDP-43 immobile bodies arise from prolonged stress through impaired
stress granule disassembly. Therefore, it is speculated that during neurodegeneration, a
critical threshold exists between stress granule disassembly and TDP-43 aggregation [137].
The presence or absence of RNA alters the formation and dynamics of TDP-43 granules.
TDP-43 binds to RNA through UG-rich sequences and these complexes are present within
phase separated structures. The presence of RNA inhibits the homo-oligomerization of
TDP-43 in granules. An optogenetic approach using a Cry2-TDP-43 construct demonstrated
that light-induced, phase-separated TDP-43 was void of RNA [136]. Alternatively, TDP-43
was shown to localize with NEAT1 and upregulation of NEAT1 promoted the LLPS of TDP-
43 [73]. Importantly, the ALS-associated p.D169G mutation impaired the assembly of TDP-
43 into NEAT-1-positive nuclear bodies, instead p.D169G translocated to the cytoplasm
and formed additional stress granules than were observed for wild-type TDP-43. However,
the ALS-associated mutant proteins p.Q331K and p.M337V did not affect nuclear body
formation [73]. Thus, while TDP-43 is important for reducing the toxicity of stress via
the formation of reversible nuclear bodies, whether this process is impaired in ALS and
FTLD remains to be determined. An endogenous mouse mutation (p.M323K) and the
ALS-associated p.Q331K mutation decreased the ability of the mutant proteins to phase
separate compared with wild-type [108]. Li et al. (2018) identified key Tryptophan residues
(Trp-334, Trp-385 and Trp-412) that are critical for LLPS, and suggest that the ~50 mutations
that manifest in the C-terminal domain may interfere with the motifs required for LLPS to
occur [135].
2.4.3. Impaired Axonal Transport
Axonal transport functions to deliver and distribute cellular growth factors, organelles,
synaptic cargoes and cytoskeletal factors to increase the efficiency of trafficking within neu-
ronal cells [139]. Impaired axonal transport is observed in mouse models and post-mortem
tissues of patients with ALS [140]. Mutant TDP-43 proteins demonstrate impaired antero-
grade movement within neurons, which is likely to play a role in neuron axon growth [29].
Axonal transport is critical to neuron function and survival [141]. Abnormal mitochondrial
trafficking and abnormal vesicles in the axon have been identified in ALS [142,143]. TDP-43
is highly mobile and is actively transported in motor neuron axons, with the level of axonal
TDP-43 increased by treatment with brain derived neurotrophic factor. Overexpression of
either wild-type (full-length) or mutant (p.M337V or p.A382T) TDP-43 in primary motor
neurons impaired axon outgrowth. Both mutant proteins were more abundant in the axons
than wild-type TDP-43 [29]. However, mutant TDP-43 expression (p. M337V or p. Q331K)
leads to impaired axonal transport in rat cortical neurons [25]. Further, the microtubule-
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dependent transport of TDP-43 mRNA granules is suppressed by ALS-associated mutations
(p.M337V or p.A315T) [21]. Transport of mitochondria is also impaired by overexpression
of either wild-type or mutant (p.Q331K, p.A315T or p.M337V) TDP-43 [144,145]. Wild-type
TDP-43 is observed to move bidirectionally within neurons for long distances with brief
pauses and displays a greater association with anterograde movement towards the NMJ.
Mutant TDP-43 (p.M337V and p.A315T) impaired the anterograde movement of TDP-43 in
neurons and altered the localization pattern of TDP-43 away from the NMJ and proximal
axons. Similar results were observed in mouse primary cortical neurons. Treatment with
nocodazole revealed that axonal transport of TDP-43 is microtubule-dependent. [21]. Thus,
TDP-43 appears to play a role in axon growth that may be dependent on its axonal transport
and appears to be impaired by ALS or FTLD-associated mutations.
2.4.4. Mitochondrial Dysfunction
Mitochondrial dysfunction has been implicated in the disease progression since the
observation of abnormal mitochondrial morphology and the identification of SOD1 muta-
tions in ALS patients [136]. SOD1 is involved in the breakdown of reactive oxygen species
(ROS) within the cell [146]. Reactive oxygen species are a byproduct of the mitochondrial
electron transport chain. Therefore, ALS was linked with dysfunctional mitochondria
through oxidative stress [146]. ALS patient tissues display abnormal mitochondrial mor-
phology [147]. As neurons have a particularly high demand for mitochondria due to
synaptic homeostasis, mitochondrial dysfunction in neurons has a significant effect on
function and survival [148]. The breakthrough discovery of TDP-43 as a pathological factor
in ALS in 2006 does not exclude mitochondrial involvement in the disease pathology of
ALS. TDP-43 links mitochondrial dysfunction to ALS and FTLD through its regulation of
nuclear-encoded mitochondrial genes [143]. Mitochondrial caspases cleave TDP-43 into
the pathological 25 and 35 kDa fragments associated with ALS and FTLD, thereby linking
mitochondrial defects and TDP-43 to disease proteinopathy [146].
TDP-43 and Mitochondrial mRNA Regulation
There is growing evidence that early mitochondrial dysfunction within upper motor
neurons leads to their vulnerability to TDP-43 proteinopathy [145]. TDP-43 is at least par-
tially localized to mitochondria within the diseased spinal cord and frontal cortex tissues of
patient samples [149]. Further, TDP-43 p.A315T mutant mice display mitochondrial defects
early in life that are restricted to motor neurons [150]. TDP-43 binds to micro RNA (miRNA)
and regulates mitochondrial mRNAs. Silencing of TDP-43 through siRNA demonstrated
that 13.01% of upregulated proteins were involved in mitochondrial processes. TDP-43 is
involved in miRNA regulation as it has been colocalized to both Drosha and Dicer, but not
Ago2. Drosha and Dicer are involved in the production of miRNAs, while Ago2 is involved
in silencing via binding and trafficking of miRNAs [146]. ALS-linked mutants enhance
miRNA trapping and subsequently increase the expression of mitochondria-bound proteins.
These differentially regulated proteins include those involved in oxidative phosphorylation
and transport porins. The mitochondrial protein imbalance generates additional ROS and
TDP-43 cleavage causing subsequent TDP-43 aggregation [146]. TDP-43 also stabilizes the
polycistronic RNA transcripts of proteins involved in the electron transport chain, tRNAs
and mitochondrial ribosomal RNAs [151]. Izumikawa et al. (2017) generated single point
mutations (K136, K145 and F147/149) to demonstrate that the RRM1 domain is critical for
regulating tRNA interaction in mitochondria. They further showed that TDP-43 overex-
pression alters mitochondrial morphology and inhibits cell proliferation [151]. Treatment
with ethidium bromide to inhibit mitochondrial transcription reduced the overexpression
effects of TDP-43 on cell proliferation. Therefore, TDP-43 regulation of mitochondrial
transcripts has global cellular effects [151].
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Mitochondrial Structural and Functional Abnormalities
Electron microscopy of patient samples revealed mitochondrial impairment. Similar
impairments, including the presence of smaller mitochondria with swollen and degen-
erated cristae, or the complete lack of cristae, were observed in cell and animal models
of overexpressed TDP-43A315T [152]. This was shown to a lesser extent in models with
wild-type TDP-43 overexpression. These degenerative changes were accompanied by
reduced membrane potential, increased ROS, reduced mitochondrial ATP and activation of
the mitochondrial unfolded protein response (UPR). The authors show that mitochondrial
impairments occur early and precede cell death [152]. In a cell line stably expressing a
25 kDa CTF, markers for mitochondrial oxidative stress were increased compared to EGFP-
expressing cells. In addition, the cells had swollen mitochondria with dilated cristae [153].
In mice expressing TDP-43A315T under the prion promoter, mitochondrial defects are ob-
served as early as postnatal day 15 indicating that they may contribute to motor neuron
vulnerability [150]. The mitochondria were distorted with compromised inner membranes
or broken outer membranes, or formed ring-like structures [150]. In cells overexpressing
wild-type, mutant (p.Q331K or p.M337V) or CTFs (TDP-25 or TDP-35), the percentage of
cells with abnormal mitochondria was increased compared to empty vector transfected
cells [154]. The number of mitochondria was reduced in cells transfected with TDP-25 or
TDP-35, which localized to mitochondria. Further, expression of CTFs was associated with
upregulation of the autophagy marker LC3-II and reduced the expression of p62, changes
that indicate that CTFs induce mitophagy [154].
Overexpression of wild-type TDP-43 decreased the length and density of mitochon-
dria in primary motor neurons. This was enhanced in cells expressing mutant (p.Q331K
or p.M337V) TDP-43 [145]. Importantly, while disease mutations (p.Q331K and p.M337V)
increase the co-localization of TDP-43 with mitochondria, inhibition of mitochondrial
localization decreases TDP-43-mediated neurotoxicity [149]. Both suppression and over-
expression of TDP-43 decreased the movement of mitochondria. Expression of mutant
TDP-43 led to reduced mitochondrial length [149]. Wang et al. (2017) showed that the
motor phenotype developed by 8 months of age in hemizygous TDP-43M337V mice could
be alleviated with the use of an inhibitor that prevented TDP-43 localization to mitochon-
dria [155]. The interaction between TDP-43 and the mitochondria appears to be mediated
through vamp-associated protein b and c [156]. In addition to, direct interaction with mito-
chondria affecting mitochondrial morphology and trafficking, TDP-43 also regulates the
expression of genes that are involved in mitophagy. Parkin is an E3 ubiquitin ligase that in
co-ordination with PTEN-induced putative kinase 1 (PINK1) is involved in mitochondrial
degradation via mitophagy [157]. Overexpression of TDP-43 decreased Parkin transcripts,
but not that of PINK1 [145]. However, there was a significant increase in the amount of
insoluble, cleaved PINK1 observed in Western blots and TDP-43 overexpression reduced
the co-localization of PINK1 to mitochondria. Further, endogenous PINK1 accumulates in
the neurons of TDP-43Q331K mice. The increase in cleaved PINK1 caused mitochondrial
dysfunction [157].
Mitochondrial involvement in the progression of ALS may be mediated via apop-
totic signals in calcium buffering and the activation of caspases. Calcium signaling is
an essential mechanism involved in normal neuronal function [158]. Signal transduction
involves the uptake and release of calcium stores to initiate electrical signaling between
synapses. C9orf72 GGGGCCn repeat sequence expansions, the most common cause of ALS
and FLTD, impairs mitochondria and the calcium balance within neurons. Low calcium
levels correlate with a low response in motor neurons through depolarization, decreasing
recovery times and neuronal function [158]. In SOD1 mutant neurons in addition to a
disruption of cellular calcium stores, impaired mitochondria generate activated caspase-1,
-3, -7 and -9. This demonstrated a link between mitochondrial imbalance and ALS [159].
Like SOD1 mutant proteins, mutant TDP-43 (p.M337V and p.I383T) also impair calcium
uptake by mitochondria [158]. Thus, TDP-43 (wild-type and mutant) may affect mitochon-
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drial structure and function through multiple mechanisms, including the production of
oxygen radicals.
Oxidative Stress
Reactive oxygen species (ROS) are produced due to electron leakage that occurs
during oxidative phosphorylation within the mitochondrial energy production pathway.
Irregularities in the regulation of ROS and reactive nitrogen species (RNS) can cause
oxidative stress. Oxidative stress can be defined as the imbalance between the production
and the clearance of ROS/RNS that may result in molecular damage [160]. Oxidative
stress has been suggested to increase with age, and harm mRNA sequences involved in
protein synthesis, and the mitochondrial electron transport chain, inducing the production
of impaired proteins. Oxidative stress is associated with mitochondrial pathways energy
deficits, calcium imbalance and apoptotic mechanisms, all of which occur in ALS [160].
The cytoplasmic mislocalization and aggregation of TDP-43 has been associated with
oxidative stress [61]. Irregular RNA processing occurs under oxidative conditions [79].
Cohen et al. (2012) used neuronal tissue in vitro to show that oxidative stress promotes
insolubility via the cross-linking of TDP-43 which is induced by cysteine oxidation and
disulphide bond formation. Increases in the amount of cross-linked TDP-43 was observed in
ALS and FTD-TDP brain samples, pointing to TDP-43 cross linking as a pathological feature
in these diseases [61]. In their investigation, oxidative stressors such as hydrogen peroxide,
arsenic and heat shock all resulted in TDP-43 insolubility. Hydrogen peroxide resulted
in TDP-43 mislocalization from the nucleus into stress granules in the cytoplasm, whilst
arsenic resulted in TDP-43 aggregates within the nucleus, both showed similar insoluble
cross-linked TDP-43 variants [61]. Oxidative stress may contribute to the pathophysiology
of ALS by acting as a trigger for stress granule formation [161]. Expression of wild-type
or mutant (p.Q331K or p.M337V) TDP-43 decreased membrane potential (∆Ψm) and was
correlated with increased ROS production. CTFs TDP-25 or TDP-35 also increased ROS
production [154]. In SH-SY5Y cells expressing TDP-43Q331K, increased levels of ROS were
observed, along with increased DNA strand breaks and apoptosis [162].
The functional connectivity of motor neurons has been investigated in an oxidative
environment (induced by arsenic) using embryonic stem cells from mouse models express-
ing either wild-type or p.M337V TDP-43 [163]. In comparison to cells expressing wild-type
TDP-43, those carrying the p.M337V mutation demonstrated reduced recruitment of pro-
teins involved in ER and endosomal-extracellular transport pathways. In response to
oxidative stress, reduced binding of mutant TDP-43M337V to the cytoplasmic poly (A)-
binding protein and eukaryotic initiation factor 4A-I, essential proteins for initiation of
stress granule formation, was observed and may be linked to the impaired stress granule
formation that is observed in the TDP-43M337V motor neurons [163]. Thus, oxidative stress
may cause irregular activity of TDP-43-mediated pathways, with the mutations leading to
impaired extracellular vesicle secretion in motor neurons [163].
2.4.5. Proteostasis
Proteostasis refers to the maintenance of protein homeostasis and balances the pro-
duction of nascently translated proteins with the degradation of misfolded or aggregated
proteins [164]. Protein quality control ensures that newly translated proteins are folded
correctly. For proteins that will be secreted or are destined for the plasma or cell mem-
branes, this occurs in the endoplasmic reticulum [165]. If a protein cannot be refolded into
the correct configuration by molecular chaperones, such as the heat shock proteins, it will
be delivered to the UPS for degradation, whereas aggregated, ubiquitinated proteins are
shuttled to the autophagy-lysosome system (autophagy) for degradation [164]. Aberrant
protein aggregation is a characteristic of neurodegenerative disorders including ALS and
FTLD, such aggregates normally constitute proteins that are misfolded and may indicate
an impairment to proteostasis mechanisms [7,166].
Int. J. Mol. Sci. 2021, 22, 4705 19 of 34
ER Stress and the Unfolded Protein Response
ER stress is a characteristic of ALS and FTLD [167,168]. When unfolded proteins
accumulate in the ER, termed ER stress, this activates various signaling pathways, termed
the UPR [169]. If ER stress is not resolved, cell death may occur [170]. Large amounts of
calcium (Ca2+) are stored in the ER. It plays a role in the ER mitochondrial calcium cycle,
which couples mitochondrial energy production and ER protein processing with neuronal
synaptic activity [167]. Interaction between the ER membrane and mitochondria is impor-
tant for metabolomic processes such as energy production, protein folding, autophagy,
apoptosis and the biogenesis and transport of mitochondria [156]. However, the mecha-
nisms that tie the ER to mitochondria are not completely understood. TDP-43 has been
shown to interrupt an interaction between the ER protein vamp-associated protein b and c
and the mitochondria localized protein tyrosine phosphatase interacting protein 51, which
together regulate the association between the ER and mitochondria [156]. Overexpression
of wild-type or mutant (p.M337V, p.Q331K, p.A382T, p.G348C) TDP-43 interrupts this
ER-mitochondria interaction, possibly via decreased interaction with VAPB. Expression of
TDP-43 was also associated with the activation of glycogen synthase kinase 3β (GSK-3β)
and disturbed Ca2+ homeostasis. Activation of GSK-3β and disrupted Ca2+ homeostasis
are observed in ALS [156]. In cell lines expressing TDP-43 p.A382T or p.M337V, Ca2+
signaling from the ER was reduced 50% compared with cells expressing wild-type TDP-
43 [171]. Decreasing the Ca2+ in wild-type TDP-43-expressing cells mimicked the cellular
phenotype of mutant TDP-43 expressing cells, indicating that TDP-43 pathology may be
linked with reduced Ca2+ [171]. In small animal models of TDP-43 proteinopathy (worms
and zebrafish), pharmacological reduction in ER stress was neuroprotective against TDP-43
proteinopathy induced by overexpression of TDP-43G348C [170]. Expression of TDP-43A315T
in SH-SY5Y cells increased cytotoxicity by activating ER stress-induced autophagy, with
cell death reduced by autophagy inhibition [172]. Thus, targeting the ER-UPR may be an
important avenue for research into new therapeutics for ALS and FTLD.
Ubiquitin-Proteasome System
If the ER is unable to refold a misfolded protein, it is shuttled to the UPS for degra-
dation [169]. The UPS is a protein degradation system in which ubiquitin is activated
and transferred to ubiquitin conjugases that then bind the ubiquitin to target substrates
with the assistance of ubiquitin ligases. Ubiquitinated proteins are then transported to
a proteasome for degradation [173]. In neurodegenerative diseases such as ALS, UPS
function may be compromised, resulting in inappropriate protein degradation and protein
accumulation, which can lead to apoptosis [174]. The level of TDP-43 in neurons is critical,
as both overexpression and knockdown of the protein in various animal models causes
neurodegeneration [37]. Overexpression of TDP-43 leads to a cellular phenotype that is
reminiscent of ALS and FTLD TDP-43 proteinopathies. This includes increased insoluble
polyubiquitinated proteins due to impaired proteasome function [175]. In neuronal cells
stably expressing TDP-25, cytotoxicity was dependent on the proteasome [153]. Of note
the cytotoxicity of overexpressed TDP-43 and that of proteasome inhibition is mediated by
phosphorylation of the ubiquitin-binding domain of the autophagy cargo receptor p62 by
tank-binding kinase 1 (TBK1) [175], which is mutated in up to 4% of ALS and FTLD cases
and up to 10.8% of FTLD-ALS cases [176]. Recently, reduced phosphorylation of p62 by a
TBK1 ALS-associated mutant protein was linked with decreased autophagic degradation
of TDP-43, suggesting that TBK1 may be a novel regulator of TDP-43 levels [177].
TDP-43, either full-length or truncated forms, can be degraded via both the UPS and
autophagy [48,178–180]. Scotter et al. (2014) showed that the pathway used for TDP-43
degradation is dependent on whether it is in soluble (UPS) or aggregated (autophagy)
form [37]. Araki et al. (2014) performed pulse chase experiments in SH-SY5Y cells stably
expressing TDP-43 mutant (p. G298S and p.A382T) proteins [181]. They showed that
these TDP-43 mutant proteins had an increased turnover compared with wild-type TDP-43,
which was partially prevented by a proteasome inhibitor, but not a lysosomal inhibitor.
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Thus, these TDP-43 mutant proteins are degraded by the UPS [181]. Of note, inhibition
of the proteasome, but not other stress conditions, induced the phosphorylation, ubiq-
uitination and cytoplasmic aggregation of TDP-43, epitomizing ALS and FTLD TDP-43
proteinopathies [182]. Additionally, motor neuron specific genetic disruption of the protea-
some, but not of autophagy, in mice led to the development of an ALS phenotype [183].
Thus, impairment of the UPS may be critical to ALS/FTLD pathology.
Autophagy
Dysfunctional autophagy is often observed in neurodegenerative disorders. Au-
tophagy is a cellular mechanism for the removal of aggregated proteins and damaged
organelles, via selective or non-selective (bulk) processes. It can be divided into mi-
croautophagy, macroautophagy or chaperone-mediated autophagy [7]. Unless otherwise
specified, the following information refers to macroautophagy, hereafter referred to as
autophagy. Neurons are uniquely susceptible to impairments in the autophagy-lysosome
system. This in part is due to being non-divisible and therefore unable to dilute toxic
protein aggregates. Additionally, while autophagosomes arise throughout the neuron, the
lysosomes that are required for proteolysis are mostly located within the soma, therefore
the autophagosome must be actively transported [7]. Thus, impairments to autophagosome
formation or maturation, impaired fusion with lysosomes, defects in transport or lysosomal
degradation have the potential to impact neurons greatly.
While TDP-43 aggregation and autophagy dysregulation have been highlighted in
ALS and FTLD pathology for some time, the role of TDP-43 in autophagy regulation was
unknown. However, knockdown of TDP-43 led to decreased expression of the critical au-
tophagy gene Atg7 [121]. This caused the accumulation of polyubiquitinated proteins and
the autophagy cargo receptor p62, suggesting that TDP-43 may form part of an autophagy
feedback regulatory loop that is potentially disrupted in TDP-43 proteinopathies [121]. A
role for TDP-43 in autophagy regulation was further demonstrated in mice homozygous
for a TDP-25 transgene, which displayed reduced induction of autophagy and impaired
proteasome function [184]. The mice showed a gene-dosage effect, as the homozygous mice
had decreased cognition and reduced motor function compared with heterozygotes [184].
Autophagy was also inhibited in a knockin TDP-43N390D mouse model. This was due to a
progressive increase in TDP-43 levels, which upregulated autophagy regulator Bcl-2, with
the mouse showing an ALS phenotype [36]. TDP-43 knockdown targeted the mammalian
target of rapamycin (mTOR) complex 1 component raptor, which in turn induced the
nuclear localization of transcription factor EB (TFEB) causing transcriptional changes to
genes that increase the biogenesis of autophagosomes and lysosomes [122]. However,
TDP-43 knockdown impaired autophagosome-lysosome fusion due to a downregulation
of dynactin 1. The effects of TDP-43 knockdown on autophagy were shown to be mTOR-
dependent (TFEB regulation) and mTOR-independent (fusion) [122]. A state of increased
autophagy induction paired with an accumulation of immature or intermediatory au-
tophagosomes occurs in neurodegenerative conditions, including Alzheimer’s disease, and
leads to overwhelm of the autophagy-lysosome system [185]. In ALS and FTLD, TDP-43
loss of function due to cytoplasmic mislocalization and/or aggregation may partly explain
the impairments in autophagosome-lysosome fusion and autophagy-mediated protein
degradation observed.
In immortalized motor neurons and stabilized myoblasts the overexpression of TDP-
25 resulted in impaired autophagy and TDP-25 was instead cleared by the proteasome [186].
In a Neura2A overexpression model, TDP-25 formed insoluble cytoplasmic aggregates
within 6 h of transfection. The amount of TDP-25 present in the insoluble fraction was
reduced by treatment with berberine, an herbal autophagy activator that works via the
inhibition of mTOR. The effects of berberine on TDP-43 aggregation were reversed by an
inhibitor of autophagosome formation (3-MA) [187]. In HEK293 cells overexpressing TDP-
43, the autophagy activator ibudilast increased the clearance of both TDP-25 aggregates and
the full-length TDP-43 aggregates that formed in response to proteasome inhibition. The
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treatment reduced the cytotoxicity associated with TDP-25 overexpression and similarly
to berberine worked via mTOR inhibition [188]. In an SH-SY5Y overexpression model,
treatment with the mTOR-independent inducer of autophagy trehalose caused TDP-43
clearance via activation of TFEB. Trehalose has shown promise as a neuroprotective agent
in various neurodegenerative diseases [189]. In an FTLD-U mouse model that exhibits
TDP-43 proteinopathy due to overexpression of wild-type TDP-43, treatment with various
autophagy activators (rapamycin, spermidine, carbamepine and tamoxifen) rescued motor
dysfunction, reducing the level of TDP-43 inclusions and CTFs generated and alleviating
caspase-mediated apoptosis [190]. Thus, autophagy inducers may be beneficial treatment
options for ALS and FTLD patients.
2.5. Non-Cell-Autonomous Mechanisms
The expression of mutant TDP-43 within non-neuronal muscle cells indicated non-
cell-autonomous effects of these proteins. Wächter et al. (2015) showed that expression of
TDP-43 p.A315T within muscle cells had a degenerative effect on motor neuron cells [191].
Healthy motor neurons were co-cultured on top of transgenic wild-type TDP-43 or the
TDP-43 p.A315T expressing muscle cells. In comparison to the controls the TDP-43A315T
motor neurons showed significantly reduced neurite outgrowth and fewer branching
points [191]. Serio et al. (2013) investigated human iPSC-derived astrocytes harboring
the p.M337V mutation and found no adverse effects on co-cultured wild-type TDP-43 or
TDP-43 p.M337V neurons. However, mislocalization of TDP-43 from the nucleus to the
cytoplasm and a decreased rate of survival compared to controls was observed in the TDP-
43 p.M337V astrocytes. Thus, astrocytes harboring mutant TDP-43 exhibit cell-autonomous
effects, but not non-cell-autonomous effects [192].
2.5.1. Gliosis
Glial cells are three times more abundant than neurons and work to support neuronal
function [193]. Gliosis is a defensive mechanism that occurs after astrocyte activation in
reaction to brain or spinal cord injury. Astrocytes are essential glial cells that are involved
in the oxidative stress response, scar formation and tissue repair [194]. Astrogliosis is a
reactive form of gliosis in which there is aberrant proliferation of astrocytes in reaction to
neuron destruction in the central nervous system [195]. Astrogliosis has been detected in
ALS/FTLD TDP-43 mouse models including those expressing the human TDP-43 p.A315T
and p.M337V proteins [196,197], overexpression of mouse TDP-43 in the forebrain [198]
and overexpression of human TDP-43 in neurons [199]. Ke et al. (2015) generated an
inducible mouse model of ALS that expresses TDP-43A315T. When doxycycline is added to
the feed expression of the transgene is suppressed. Expression of TDP-43A315T induced a
neurodegenerative phenotype that included pronounced activation of astrocytes. Impor-
tantly, when the expression of the transgene was suppressed motor and behavioral deficits
were improved [200]. In a detailed characterization of a distinct TDP-43A315T mouse, Barg-
sted et al. (2017) observed a significant loss of motor neurons, axonal degeneration and
activation of astrocytes and microglia. Primary astrocytes isolated from another transgenic
hTDP-43A315T mouse had impaired L-glutamine uptake and abnormal accumulation of
ATP [201]. In addition, a significant increase in astrocyte activation was associated with mo-
tor neuron loss, suggesting that mutant TDP-43 may contribute to ALS via cell-autonomous
and non-cell-autonomous mechanisms [201]. Expression of TDP-43M337V in astrocytes in
rats led to the activation of both astrocytes and microglia and motor neuron loss [202].
However, in a doxycycline repression mouse model expressing TDP-43-∆NLS, only subtle
effects on microglia were seen despite significant motor neuron loss [203]. Yet, when the
expression of the transgene was repressed, microglia proliferated and cleared TDP-43,
indicating a role for these cells in neuroprotection [203].
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2.5.2. Prion-Like Propagation
Prion diseases involve the propagation of infectious particles of proteinaceous origin,
leading to neurodegenerative diseases [204]. The production of amyloid-like species may
be important to propagation and is associated with many neurodegenerative disorders.
TDP-43 can form amyloid-like species, and this may be mediated by the low complexity
C-terminal domain that is often mutated in ALS or the RRM domains [205–207]. This low
complexity domain may impart prion-like properties [204]. Of note, TDP-43 mutations
(p.A315E and p.A315T) convert TDP-43 into insoluble, irreversible aggregates [207]. Ap-
plication of recombinant full-length aggregates of TDP-43 to cells exogenously expressing
TDP-43 induces intracellular aggregation of TDP-43, proving that TDP-43 can seed aggrega-
tion [208]. Self-templating of TDP-43 aggregation was observed when the insoluble protein
fractions obtained from human ALS- or TDP-43-positive FTLD tissue samples were applied
to neuronal cells overexpressing TDP-43 [209]. This finding has since been confirmed in var-
ious studies using stable cells, cells overexpressing TDP-43 and co-cultured cells [210–212].
A further study showed that TDP-43 seeds are show trans-synaptic spreading [213]. Thus,




AMP-activated protein kinase (AMPK) is an energy metabolism and stress pathway
regulator. AMPK senses imbalance between ATP and AMP in the cell, often caused by
oxidative stress or nutrient deprivation, and responds by activating glucose uptake, and
autophagy, while decreasing protein translation and glycogen synthesis [214]. Activation of
AMPK was shown to be reduced in the central nervous system of TDP-43A315T mice [215].
During the presymptomatic stages of the disease, TDP-43A315T demonstrated a reduction
of 60% and 80% in the spinal cord and brain tissue, respectively. Once TDP-43A315T mice
were symptomatic, the activation of AMPK was reduced by 30% and 60% in the spinal
cord and brain, respectively. Therefore, TDP-43 leads to reduced central nervous system
AMPK activation, most potently in symptomatic ALS. By contrast, SOD1G93A patients
showed over activated AMPK [215].
Expression of phosphatases, which dephosphorylate AMPK, was assessed in the
TDP-43A315T mice. Protein phosphatase 2A (PP2A) was significantly increased in TDP-
43A315T mice and correlated with reduced activation of AMPK. In NSC-34 cells expressing
TDP-43Q331K and TDP-43M337V AMPK activation was reduced to 50% and 70%, respec-
tively, when compared with cells expressing wild-type TDP-43 [215]. Concurrently, cells
expressing TDP-43Q331K and TDP-43M337V showed 40% and 120% increased expression
of PP2A, respectively. Confirming that TDP-43 caused AMPK inactivation via PP2A, the
inhibition of PP2A resulted in AMPK activation in cells expressing either wild-type or
mutant TDP-43. Therefore, targeting AMPK inactivation via PP2A inhibition may represent
a model for therapeutics in patients with TDP-43 proteinopathies [215].
3. Discussion
TDP-43 is the primary pathogenic protein observed in almost all cases of ALS and
the majority of non-tau-related FTLD. Expression of mutant proteins or overexpression of
wild-type TDP-43 decreased axon outgrowth [29]. Mutant TDP-43 leads to denervation of
neuromuscular junctions and decreased neuron viability [26,36]. However, the mechanisms
underlying toxicity in cells expressing either mutant TDP-43 or overexpressing wild-
type TDP-43 are incompletely understood. There is no overarching common disease
mechanism that has been identified for all mutant proteins. It is possible that stress or
mutations impair TDP-43 autoregulation, leading to increased expression of TDP-43. As
TDP-43 is prone to aggregation, increased expression may promote misfolding or may
prompt translocation into the cytoplasm where PTMs occur (Figure 2). Conversely, PTMs
may promote misfolding and translocation. Further investigation is required to fully
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elucidate the mechanisms that lead to PTMs and TDP-43 cytoplasmic translocation. These
modifications include hyper-phosphorylation, ubiquitination, SUMOlyation, acetylation
and cleavage. It is critical to understand how translocation and modification are linked
in order to understand the pathogenesis of these diseases. Further, the full consequences
of these post-translational changes need to be elucidated to enable the development of
effective treatments.
Figure 2. Molecular mechanisms underlying TDP-43 pathogenesis in response to mutations or stress. Mutations in TARDBP
or other genes associated with ALS and FTLD, or exposure to oxidative stress or heavy metals such as arsenite, impair
TDP-43 function. Specifically, TDP-43 autoregulation and nuclear:cytoplasmic shuttling is impaired, leading to a loss of
RNA metabolism and increased cytoplasmic TDP-43. Mislocalization of TDP-43 increases its tendency to aggregate. Post-
translational modifications occur including hyper-phosphorylation (P), acetylation, ubiquitination (Ub), SUMOylation (S), or
PARylation, as well as cleavage/fragmentation, which promotes TDP-43 aggregation. The nuclear depletion, misfolding and
cytoplasmic aggregation of TDP-43 leads to (1) dysregulation of RNA metabolism including splicing defects, (2) impaired
mitochondrial function and axonal transport, (3) impaired proteostasis (UPS and autophagy), (4) abnormal stress granule
dynamics and (5) amyloid-like aggregate formation that may be spread cell to cell in a prion-like manner.
CTFs are observed in tissues from ALS and FTLD patients [16,18,45]. Cell models
show that expression of various ALS-associated mutant proteins leads to the production
of CTFs, which are hyperphosphorylated, aggregated and toxic [50–54]. Further studies
show that cleavage and phosphorylation appear to occur post-aggregation [47]. It was
thought that aggregation may be critical to the cytotoxicity of mutant proteins. However,
overexpressed wild-type TDP-43 is toxic while tending not to aggregate [27]. Further,
studies in transgenic mice show that it is translocation from the nucleus to the cytoplasm
that is associated with a neuromuscular phenotype. In mice expressing TDP-43-∆NLS
neurodegeneration was observed despite the TDP-43-∆NLS only occurring in cytoplasmic
aggregates in a low proportion of cells [60]. Thus, the critical factor in pathogenesis
appears to be TDP-43 translocation out of the nucleus. Many mutant proteins show
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increased cytoplasmic localization and/or decreased nuclear localization [25,28,56,72].
TDP-43 shuttles out of the nucleus through passive diffusion. However, it is unknown
what causes TDP-43 translocation in ALS and FTLD. It is possible that in response to
cellular stress or mutations, TDP-43 levels reach a critical point at which translocation
occurs. This leads to a loss of function concerning TDP-43 regulation of RNA processing.
Thus, while cytoplasmic aggregation of TDP-43 is a characteristic sign of pathology in these
diseases, it appears that it is the mislocalization of TDP-43 into the cytoplasm that confers
toxicity, with dysfunctional RNA metabolism likely critical to pathogenesis.
TDP-43 regulates the metabolism, splicing and transport of 1000s of mRNAs [90].
Expression of mutant TDP-43 decreased the motility of mRNP granules, reducing the
transport of mRNAs, led to exon exclusion of some pre-mRNAs and increased normal
splicing or translation of other targets [21,95,106,109,110]. In animal models expressing
mutant TDP-43 deregulated splicing and alternative splicing was observed [109,110]. Thus,
in ALS and FTLD cases where a TARDBP mutation leads to cytoplasmic mislocalization,
or in sporadic cases where an unknown trigger causes translocation, the normal RNA
regulatory functions of TDP-43 may be severely reduced and contribute to pathogenicity.
Therefore, strategies to reduce TDP-43 nuclear depletion are an attractive approach to
the effective treatment of ALS and FTLD. As deficiency and TDP-43 overexpression have
profound effects on neuron viability and function [25,26,29,34], direct targeting of TDP-43
is a major roadblock to disease-modifying treatments. Therefore, targeting key factors that
contribute to TDP-43 aggregation in neurons offers an alternative and original therapeutic
approach. Further research to fully elucidate those triggers and identify the factors that
trigger TDP-43 translocation are required.
4. Conclusions
Overall, the literature suggests that TDP-43 proteinopathy occurs due to the transloca-
tion of TDP-43 out of the nucleus into the cytoplasm. This may occur due to stressors that
induce ROS generation, or the presence of a gene mutation. Either may lead to a loss of
nuclear function, including altered splicing and translation of mRNAs, and a gain of toxic
functions in the cytoplasm, including dysregulated proteostasis, impaired mitochondria,
activation of ER-induced cell death and impaired stress granule formation. The major
unresolved questions are the following: are PTMs or TDP-43 misfolding a cause of disease
or a result of pathogenesis? And do they induce TDP-43 translocation out of the nucleus?
In answering these questions, we can tackle the problem of how to prevent PTMs and
mislocalization from occurring. This will help to identify therapeutic targets, which may
include chaperones involved in the folding of TDP-43.
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Abbreviations
aa amino acid
ALS amyotrophic lateral sclerosis
AMP adenosine 3′, 5′-monophosphate
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropinionic acid
AMPK AMP-activated protein kinase
Ca2+ calcium
CK1 casein kinase 1ε
CTF C-terminal fragment
eIF2α eukaryotic initiation factor 2 alpha
EEAT2 excitatory amino acid transporter 2
ENU N -ethyl-N-nitrosurea
ER endoplasmic reticulum
FTD-TDP frontotemporal degeneration associated with TDP-43 pathology
FTLD frontotemporal lobar degeneration
G3BP RasGAP-association endoribonuclease
G4-RNA G-quadruplex-RNA
GSK-3β glycogen synthase kinase 3β
LLPS liquid–liquid phase separation
MALAT metastasis-associated lung adenocarcinoma transcript 1 (also known as NEAT2;
nuclear paraspeckle assembly transcript 2)
miRNA micro RNA
mRNA messenger ribonucleic acid
mTOR mammalian target of rapamycin
NEAT1 nuclear paraspeckle assembly transcript 1
NES nuclear export signal
NeuN neuronal nuclei
neuroLNC neuron-specific long-non-coding RNA
NLS nuclear localization signal
NMJ neuromuscular junction
PARP-1 poly-(ADP-ribose) polymerase-1
PINK1 PTEN-induced putative kinase 1





RNS reactive nitrogen species
ROS reactive oxygen species
RRM RNA recognition motif
SURF SMG1, UPF1 and eRF1 and 2
TARDBP TAR-DNA-binding protein 43
TBK1 tank-binding kinase 1
TDP-43 TAR-DNA-binding protein 43
TFEB transcription factor EB
TIA-1 T-cell intracellular antigen 1
UPR unfolded protein response
UPS ubiquitin proteasome system
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